Menu
Not yet recruiting NCT07209670

Umbilical Venous Versus Peripherally Inserted Central Catheters in Neonates: A Prospective Cohort Study of Complications, Catheter Survival, and CLABSI"

— Observational Peripherally Inserted Central Catheter Umbilical Venous Catheter CLABSI - Central Line Associated Bloodstream Infection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: peripherally inserted central catheter insertion, umbilical venous catheters insertion.
Who it may be relevant to
Registry conditions: Peripherally Inserted Central Catheter, Umbilical Venous Catheter, CLABSI - Central Line Associated Bloodstream Infection. Basic parameters: 0 Days — 28 Days · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study aims to prospectively compare umbilical venous catheters (UVCs) and peripherally inserted central catheters (PICCs) in neonates, focusing on complications, catheter survival, and central line-associated bloodstream infection (CLABSI) rates

Interventions

  • Procedure peripherally inserted central catheter insertion
    Neonates who received peripherally inserted central catheters within the first 28 days of life.
  • Procedure umbilical venous catheters insertion
    Neonates who received umbilical venous catheters within the first 28 days of life

Primary outcome measures

  • catheter survival time [Time frame: From catheter insertion until removal (up to 28 days of life or until hospital discharge, whichever occurs first)]
  • Central Line-Associated Bloodstream Infection (CLABSI) Incidence [Time frame: During the entire catheterization period (up to 28 days of life or until hospital discharge]

Eligibility criteria

Inclusion criteria

  • Neonates admitted to the neonatal intensive care unit (NICU) requiring central venous access.
  • Infants in whom either an umbilical venous catheter (UVC) or a peripherally inserted central catheter (PICC) was inserted for clinical indications (Parenteral nutrition, administration of intravenous medications (e.g., antibiotics, inotropes, anticonvulsants, fluids) and blood sampling for frequent labs, especially in critically ill neonates).
  • Catheter insertion performed within the first 28 days of life.

Exclusion criteria

  • Neonates with major congenital anomalies (e.g.abdominal wall defects) that may interfere with catheter placement or outcomes.
  • Insertion site infection
  • Infants with severe coagulopathy or bleeding disorders contraindicating central catheter insertion.
  • Neonates who received both UVC and PICC simultaneously during the same admission.
  • Cases with incomplete clinical records or missing follow-up data.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07209670 · venous catheters in neonates

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗